VIVS - Organovo Company Value to Earnings Growth Ratio

Brandmark of Organovo (VIVS)

VivoSim Labs Inc adapts 3D bioprinting for preclinical testing for pharmaceutical companies. The P/E ratio relative to medium-term growth demonstrates current dynamics, where the 0.00 mark indicates the asset's valuation level. Growth potential is based on high-tech laboratories in the US and global recognition of living organ models that accelerate the development of new drugs.

VivoSim Labs Inc (VIVS): PEG Multiple from 04/25/2025 to 11/12/2026

Metric breakdowns and analytics for Organovo (VIVS)

- price and consensus price forecast:
Market Chart VivoSim Labs Inc|VIVS - Consensus Target
- market capitalization statistics:
Market Value Organovo Holdings Inc.|VIVS - Enterprise Value
- book capitalization information:
Net Assets per Share Organovo|VIVS - Book Capitalization|Market Cap to Net Assets Ratio organovo.com|VIVS - Cumulative Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio VivoSim Labs Inc|VIVS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Organovo Holdings|VIVS - Company Aggregate Debts|Debts to Book Value Organovo Holdings Inc.|VIVS - Company Long-Term Debts|Company Short-Term Indebtedness Organovo|Interim Coverage Ratio organovo.com
- net income and valuation ratios data:
VIVS - Net Profit|Future Profit VivoSim Labs Inc|VIVS - P/E Multiple|Forward P/E Multiple VivoSim Labs|VIVS - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Organovo Holdings Inc.|VIVS - Operating profit before deduction of amortization|Earnings per share for the trailing year Organovo|VIVS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months organovo.com|VIVS - Earnings per share growth in current year|Net earnings per one share growth forecast for next year VivoSim Labs Inc
General company analysis:VIVS - Organovo Holdings Inc.
Finished products of Organovo Holdings, Inc.

The development of VivoSim Labs Inc (VIVS) in the field of 3D tissue bioprinting to accelerate pharmaceutical testing is clearly reflected in the PEG ratio trend. This indicator compares the market value of earnings with business expansion rates to determine the fairness of the growth premium; a value below one signals that the asset is undervalued, transforming it into a promising instrument with high expected returns.

Competing companies

Growth-Adjusted Market Cap to Net Income Abbott Labs|Thermo Fisher Corp - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio GEHC (GE HealthCare Inc.)|Mettler-Toledo International - PEG Multiple|Growth-Adjusted Market Cap to Net Income waters.com WAT|TECH: PEG Multiple|Price/Earnings to Growth Multiple Bruker Corp|Price/Earnings to Growth Multiple AZTA|VREX: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Semler Scientific, Inc. (SMLR)|Price/Earnings to Growth Multiple butterflynetwork.com BFLY|PEG Multiple MLAB (Mesa Labs)|Quantum-Si Inc. (QSI) - Price to Earnings Adjusted for Growth Rate|Nanox - PEG Multiple|QTRX (Quanterix Inc) - Growth-Adjusted P/E Ratio|MASS: PEG Multiple|CV - Growth-Adjusted Market Cap to Net Income|MXCT (MaxCyte) - PEG Multiple|Price/Earnings to Growth Multiple Rapid Micro (RPID)|PEG Multiple SEER|PEG Multiple Hyperfine Medical (HYPR)|Price/Earnings to Growth Ratio FONAR Corporation FONR|Daxor Corp - Price/Earnings to Growth Ratio|MDAI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ACON (Aclarion Inc)|AKYA: PEG Multiple|Price to Earnings Adjusted for Growth Rate Cesca Therapeutics (THMO)|Price/Earnings to Growth Ratio Talis Biomedical Corp.|TTOO - Price to Net Income Growth Ratio